Novel aerosol formulation containing a polar fluorinated molecule
申请人:——
公开号:US20030194378A1
公开(公告)日:2003-10-16
The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.
NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE
申请人:AstraZeneca AB
公开号:EP1303258A1
公开(公告)日:2003-04-23
[EN] NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE<br/>[FR] NOUVELLE PREPARATION EN AEROSOL CONTENANT UNE MOLECULE FLUOREE POLAIRE
申请人:ASTRAZENECA AB
公开号:WO2002003958A1
公开(公告)日:2002-01-17
The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.
CHEPIK, S. D.;BELENKIJ, G. G.;CHERSTKOV, V. F.;STERLIN, S. R.;GERMAN, L. +, IZV. AN CCCP. CEP. XIM.,(1991) N, S. 513-516
作者:CHEPIK, S. D.、BELENKIJ, G. G.、CHERSTKOV, V. F.、STERLIN, S. R.、GERMAN, L. +